CT Financial Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

CT Financial Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$37.8K	Hold	4,500	–	–	0.02%	296
2016 Q4	$28.5K	Hold	4,500	–	–	0.02%	318
2016 Q3	$19.8K	Hold	4,500	–	–	0.01%	354
2016 Q2	$12.8K	Buy	4,500 +1,500	+50%	+$4.66K	0.01%	400
2016 Q1	$8.49K	Buy	3,000 +2,000	+200%	+$8.86K	﹤0.01%	465
2015 Q4	$10.3K	Hold	1,000	–	–	0.01%	449
2015 Q3	$11.4K	Hold	1,000	–	–	0.01%	442
2015 Q2	$14.9K	Hold	1,000	–	–	0.01%	422
2015 Q1	$9.03K	Buy	+1,000	New	+$10.4K	0.01%	476
2014 Q1	$9.03K	Buy	+1,000	New	+$10.7K	0.01%	476

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CT Financial Advisors's BCRX Position: Q1 2017 in Review

CT Financial Advisors held its BioCryst Pharmaceuticals (BCRX) position steady in Q1 2017 at 4,500 shares worth $37.8K. The position accounts for 0.02% of the portfolio, ranked #296.

CT Financial Advisors first reported a position in BCRX in Q1 2014 and has held it in 10 quarters since. 117 funds tracked by Wall St. Rank hold BCRX as of Q1 2017.

CT Financial Advisors held 4,500 shares of BioCryst Pharmaceuticals worth $37.8K as of Q1 2017.
CT Financial Advisors left its BioCryst Pharmaceuticals share count unchanged in Q1 2017.
BioCryst Pharmaceuticals made up 0.02% of CT Financial Advisors's portfolio in Q1 2017, its #296 holding.
CT Financial Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2014 and has held it in 10 quarters since.
117 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2017.

Based on CT Financial Advisors's 13F filing for Q1 2017, filed 7 Apr 2017.